[go: up one dir, main page]

CY1114873T1 - Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων στην αντιμετωπιση διαταραχων της ορασης - Google Patents

Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων στην αντιμετωπιση διαταραχων της ορασης

Info

Publication number
CY1114873T1
CY1114873T1 CY20141100096T CY141100096T CY1114873T1 CY 1114873 T1 CY1114873 T1 CY 1114873T1 CY 20141100096 T CY20141100096 T CY 20141100096T CY 141100096 T CY141100096 T CY 141100096T CY 1114873 T1 CY1114873 T1 CY 1114873T1
Authority
CY
Cyprus
Prior art keywords
methods
producers
retinal
treatment
vision disorders
Prior art date
Application number
CY20141100096T
Other languages
English (en)
Inventor
Krzysztof Palczewski
Matthew Batten
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of CY1114873T1 publication Critical patent/CY1114873T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Συνθέσεις και μέθοδοι για τη χρήση συνθετικών παραγώγων ρετινάλης ενόσω παρέχονται υποκαταστάτες ρετινοειδών και αγωνιστές οψίνης.
CY20141100096T 2004-06-18 2014-02-05 Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων στην αντιμετωπιση διαταραχων της ορασης CY1114873T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
EP05773576.3A EP1765322B1 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (1)

Publication Number Publication Date
CY1114873T1 true CY1114873T1 (el) 2016-12-14

Family

ID=35782277

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20141100096T CY1114873T1 (el) 2004-06-18 2014-02-05 Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων στην αντιμετωπιση διαταραχων της ορασης
CY20171101089T CY1119480T1 (el) 2004-06-18 2017-10-18 Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων για τη θεραπευτικη αντιμετωπιση διαταραχων της ορασης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171101089T CY1119480T1 (el) 2004-06-18 2017-10-18 Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων για τη θεραπευτικη αντιμετωπιση διαταραχων της ορασης

Country Status (26)

Country Link
US (8) US7951841B2 (el)
EP (5) EP2397130B1 (el)
JP (2) JP5166026B2 (el)
KR (4) KR101323122B1 (el)
CN (2) CN1988898B (el)
AU (1) AU2005257997B2 (el)
BR (1) BRPI0511396B1 (el)
CA (2) CA2931917A1 (el)
CY (2) CY1114873T1 (el)
DK (2) DK1765322T3 (el)
ES (4) ES2644984T3 (el)
HR (1) HRP20140116T1 (el)
HU (1) HUE036596T2 (el)
IL (4) IL180078A (el)
IN (1) IN2012DN09335A (el)
LT (1) LT2397133T (el)
MX (2) MX359668B (el)
NO (1) NO339969B1 (el)
NZ (2) NZ587006A (el)
PL (2) PL1765322T3 (el)
PT (2) PT2397133T (el)
RS (1) RS53178B (el)
RU (2) RU2408578C2 (el)
SI (2) SI2397133T1 (el)
WO (1) WO2006002097A2 (el)
ZA (1) ZA200700368B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
DK1765322T3 (da) * 2004-06-18 2014-02-10 Univ Washington Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
SG144145A1 (en) * 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
US20100104644A1 (en) * 2006-07-27 2010-04-29 University Of Florida Research Foundation, Inc. Compositions and Methods for Treating or Preventing Ophthalmic Disease
WO2008063768A2 (en) * 2006-10-12 2008-05-29 Case Western Reserve University Compositions and methods for treating metabolic diseases
CA2681850C (en) 2007-04-20 2013-07-23 Acucela Inc. Styrenyl derivative compounds for treating ophthalmic diseases and disorders
NZ617701A (en) * 2008-02-11 2015-06-26 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2009133552A2 (en) * 2008-04-29 2009-11-05 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
IN2012DN00352A (el) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
MX2012003220A (es) * 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
BR112012026939A2 (pt) * 2010-04-19 2016-07-12 Quadra Logic Tech Inc método para tratamento de um paciente sofrendo da perda ou debilitação da visão
CA3056186A1 (en) * 2010-11-05 2012-05-10 Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
PT2819667T (pt) * 2012-03-01 2020-03-31 Retinagenix Therapeutics Inc Derivados de retinal para utilização na melhoria da função visual
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
RU2756403C2 (ru) * 2016-04-28 2021-09-30 Спарк Терапьютикс, Инк. Анализ относительной активности вирусного вектора, кодирующего изомерогидролазы
JP2025504092A (ja) * 2022-02-04 2025-02-06 ニューヨーク ユニバーシティ 心房細動の処置のためのレチノイドの使用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) * 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
RU2106843C1 (ru) * 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
PL322624A1 (en) * 1995-04-03 1998-02-02 Johnson & Johnson Consumer Skin care composition containing retinoides and liposomes
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
DE60130872T2 (de) 2000-03-10 2008-07-17 Insite Vision, Inc., Alameda Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
JP4210115B2 (ja) 2001-01-11 2009-01-14 チェビジェン・インコーポレイテッド 新規レチノール誘導体および製造方法および用途
US6878747B2 (en) 2001-01-26 2005-04-12 Steven A. Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
CA2474154A1 (en) 2002-01-18 2003-07-24 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP2006512279A (ja) 2002-03-29 2006-04-13 マキシム ファーマシューティカルス，インコーポレイテッド 眼内損傷を治療および予防するためのｒｏｍ生成および放出阻害剤の使用
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
PL380611A1 (pl) 2004-02-17 2007-02-19 President And Fellows Of Harvard College Postępowanie z zaburzeniami oftalmologicznymi, włącznie ze zwyrodnieniem plamki
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
DK1765322T3 (da) 2004-06-18 2014-02-10 Univ Washington Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
EP1778207A2 (en) 2004-08-18 2007-05-02 Sytera Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
EP2687208A1 (en) 2007-09-12 2014-01-22 The Trustees of Columbia University in the City of New York Compositions and Methods for Treating Macular Degeneration
NZ617701A (en) 2008-02-11 2015-06-26 Univ Washington Methods for the treatment and prevention of age-related retinal dysfunction

Also Published As

Publication number Publication date
EP2397132A3 (en) 2012-07-11
US9388130B2 (en) 2016-07-12
RU2408578C2 (ru) 2011-01-10
MX359668B (es) 2018-10-05
NO20070330L (no) 2007-03-15
PL2397133T3 (pl) 2018-01-31
KR20140140616A (ko) 2014-12-09
PL1765322T3 (pl) 2014-04-30
BRPI0511396B1 (pt) 2021-07-27
CN102976937A (zh) 2013-03-20
US10117845B2 (en) 2018-11-06
CA2931917A1 (en) 2006-01-05
US9162978B2 (en) 2015-10-20
JP2008503496A (ja) 2008-02-07
BRPI0511396A (pt) 2007-12-04
ES2443194T3 (es) 2014-02-18
EP1765322B1 (en) 2013-11-06
NO339969B1 (no) 2017-02-20
JP5166026B2 (ja) 2013-03-21
HUE036596T2 (hu) 2018-07-30
US20170014368A1 (en) 2017-01-19
ES2644984T3 (es) 2017-12-01
CN1988898A (zh) 2007-06-27
EP1765322A4 (en) 2008-09-17
IL230242A (en) 2015-10-29
US9403765B2 (en) 2016-08-02
RU2554003C2 (ru) 2015-06-20
AU2005257997B2 (en) 2012-04-05
JP2012229234A (ja) 2012-11-22
PT2397133T (pt) 2017-10-23
US20110288170A1 (en) 2011-11-24
HRP20140116T1 (hr) 2014-03-28
IL222347A (en) 2017-08-31
IL230241A (en) 2015-06-30
EP2397130B1 (en) 2019-04-03
EP2397133A3 (en) 2012-07-11
RS53178B (sr) 2014-06-30
US20130072556A1 (en) 2013-03-21
CN102976937B (zh) 2016-12-21
ES2752924T3 (es) 2020-04-06
EP2397131A2 (en) 2011-12-21
WO2006002097A3 (en) 2006-05-04
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
US7951841B2 (en) 2011-05-31
ZA200700368B (en) 2008-10-29
HK1098696A1 (en) 2007-07-27
KR20130079669A (ko) 2013-07-10
EP2397133B1 (en) 2017-07-26
US20080221208A1 (en) 2008-09-11
EP2397130A3 (en) 2012-10-31
NZ552080A (en) 2011-03-31
US20190167626A1 (en) 2019-06-06
WO2006002097A2 (en) 2006-01-05
RU2007101735A (ru) 2008-07-27
EP2397131B1 (en) 2019-09-11
EP2397132A2 (en) 2011-12-21
JP5596749B2 (ja) 2014-09-24
PT1765322E (pt) 2014-02-05
KR20070026817A (ko) 2007-03-08
DK1765322T3 (da) 2014-02-10
CA2571049C (en) 2016-08-09
CA2571049A1 (en) 2006-01-05
KR101323122B1 (ko) 2013-10-30
MXPA06014750A (es) 2007-03-21
AU2005257997A1 (en) 2006-01-05
SI2397133T1 (sl) 2017-12-29
KR101490145B1 (ko) 2015-02-05
US9174936B2 (en) 2015-11-03
LT2397133T (lt) 2018-01-10
CN1988898B (zh) 2012-12-26
EP2397131A3 (en) 2012-10-31
US20130072559A1 (en) 2013-03-21
IL180078A (en) 2014-01-30
US20130079403A1 (en) 2013-03-28
EP2397130A2 (en) 2011-12-21
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
RU2010138410A (ru) 2012-03-27
US20130072560A1 (en) 2013-03-21
SI1765322T1 (sl) 2014-03-31
CY1119480T1 (el) 2018-03-07
IL180078A0 (en) 2007-05-15
US9169204B2 (en) 2015-10-27
EP2397133A2 (en) 2011-12-21
IN2012DN09335A (el) 2015-08-21
ES2644981T3 (es) 2017-12-01
NZ587006A (en) 2011-12-22
EP1765322A2 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
CY1114873T1 (el) Παραγωγα ρετιναλης και μεθοδοι για τη χρηση αυτων στην αντιμετωπιση διαταραχων της ορασης
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
CY1120154T1 (el) Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
CY1110046T1 (el) Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων
WO2004082622A3 (en) Retinoid replacements and opsin agonists and methods for the use thereof
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1113108T1 (el) Μεσυλικο προφαρμακου λεβοντοπα, συνθεσεις αυτου, και χρησεις αυτου
HUS1600021I1 (hu) MEK inhibitorok és módszerek azok felhasználására
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
CY1113734T1 (el) Χημικες ενωσεις
ECSP078030A (es) Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
DE602005017753D1 (de) Mittel für die transdermale verabreichung von nikotin
MY135829A (en) Analeptic and drug combinations
CY1114811T1 (el) Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων
CY1108809T1 (el) Μεθοδοι κατασκευης 6-[(4.5-διϋδρο-1η-ιμιδαζολ-2-υλ)αμινο-]-7-μεθυλ-1η-βενζιμιδαζολο-4-kapboniτριλιου και προτιμωμενη μορφη αλατος αυτου
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu